The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics
ConclusionThe LoDoCo2 Trial will provide information on the efficacy and safety of low-dose colchicine for secondary prevention in patients with stable coronary artery disease.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Brain | Cardiology | Cardiovascular | Colchicine | Colcrys | Gastroenterology | Heart | Heart Attack | Ischemic Stroke | Neurology | Stroke | Study